Vandetanib instructions

1. Name: Vandetanib, Vandetanib, Caprelsa, Vandetanib

2. Indications:

Vandetanib (Vandetanib) is indicated for the treatment of patients with symptomatic or progressive medullary thyroid carcinoma (MTC) who have unresectable locally advanced or metastatic disease.

Vandetanib should be used in patients with indolent, asymptomatic, or slowly progressive disease only after careful consideration of the risks associated with treatment with vandetanib.

3. Usage and dosage:

1. Recommended dose: The recommended dose of vandetanib is 300 mg orally once a day until the disease worsens or unacceptable toxicity occurs. Do not take missed doses within 12 hours after the next dose. Vandetanib tablets can be dispersed in 2 ounces of water (it will not completely dissolve) by stirring for approximately 10 minutes. Do not use other liquids for dispersion. Swallow immediately after dispersion and mix any remaining residue with another 4 ounces of water and swallow. Vandetanib may also be administered via a nasogastric or gastrostomy tube.

2. Dose adjustment: For patients who experience grade 3 or higher toxicity after taking the drug, reduce the daily dose of vandetanib from 300 mg to 200 mg, and then to 100 mg; for patients with moderate (creatinine clearance ≥30 to <50 mL/min) renal impairment, the starting dose is reduced to 200 mg; it is not recommended for patients with moderate and severe liver impairment.

4. Adverse reactions:

The most common adverse events with vandetanib include diarrhea, nausea, fatigue, rash, acne, hypertension, headache, anorexia, and abdominal pain. Less common but potentially serious side effects include QTc interval prolongation, heart failure, sudden death, severe skin toxicity, Stevens-Johnson syndrome, interstitial lung disease, bleeding, ischemic cerebrovascular events, reversible posterior leukoencephalopathy syndrome, and embryo-fetal toxicity.

5. Storage:

Vandertanib should be storedat room temperature between 68°F and 77°F (20°C and 25°C); tolerance is 59°F–86°F (15°C and 30°C). Do not crush vandetanib tablets.

6. Taboo:

Congenital long-term syndromeDo not use vandetanib in patients with QT syndrome.

7. Mechanism of action:

In vitro studies have shown that vandetanib inhibits the tyrosine kinase activity of members of the EGFR and VEGFR families, RET, BRK, TIE2, and EPH receptor and Src kinase families. These receptor tyrosine kinases are involved in normal cellular functions and pathological processes, such as tumorigenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment. In addition, the drug's N-desmethyl metabolite (accounting for 7% to 17.1% of vandetanib exposure) has inhibitory activity at VEGF receptors (KDR and Flt-1) and EGFR similar to the parent compound.

The original drug vandetanib has not yet been marketed in China, so it is not included in medical insurance. The original drug specifications of vandetanib listed overseasThe price of each box of 300mg*30 tablets may be more than 30,000 yuan (the price may fluctuate due to the exchange rate). There is currently no generic drug of vandetanib produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.